Rising India Inc (OTCMKTS:RSII) is a media holding company that develops and markets various international media projects. It has announced acquisitions, joint-ventures and/or mergers with operating film and media operations pertaining to support and transactional businesses within the film and media industry.
Shares were up 39.13% to $0.00960 and were unchanged in after-hours trading. The company has a market cap of $3.44 million. Its Rising Biosciences Inc division is a research and development company focusing on oral and topical pharmaceuticals with strict standards set forward by the pharmaceutical compounding industry.
The company announced that it has entered in the FDA testing phase on its revolutionary medical creams for chronic pain relief and neuropathic pain. These pain creams will be the first in a series of products for a full suite of OTC chronic pain relief medications for neuropathy, muscle and tendon pain, arthritis, and treatment, as well as its skin serum for scars, wrinkles and stretch marks.
“Our partnering facility is an ISO 22716 Certified, cGMP compliant, and FDA Registered factory that utilizes the latest in technological equipment to manufacture products as quickly as possible, under the highest quality standards. Our team works in a state-of-the-art, in-house laboratory, and highly experienced chemists for advanced formulation and manufacturing,” stated Doug Bowes, Director of Brand Development for Rising Biosciences Inc.
CEO Robert Weber stated that product samples were shipped to dozens of recipients on June 13, 2017 and the feedback continues to be overwhelmingly positive.
“We can’t help be excited for the future for Rising BioSciences and its shareholders. With a finalized merger and products undergoing testing for FDA approval, we are on the cusp of delivering effective, non-opiate medication nationwide; using alternative medicine, including both Cannabis and non-Cannabis based solutions,” said Rising Indias Inc CEO Weber.
“We are assertively driving the Company toward monetization with initiatives to distribute the first two products in Q4 2017. All the while well be running testing and manufacturing details on subsequent products in our pain relief and skin serum lines,” he added.